Shares of pharma major Aurobindo Pharma gained 3% on 12 February after the company posted strong quarterly growth for October-December.

The pharma company reported a 91% year-on-year increase in its net profit to Rs 936.2 crore for the quarter under review from Rs 491.2 crore reported in the same quarter of the previous fiscal year.

The revenue from the operation of the company during the quarter stood at Rs 7,351.7 crore, marking a 14.7% YoY increase from Rs 6,407 crore reported in the same quarter last year.

The EBITDA (earnings before interest, taxes, depreciation and amortisation) during the quarter stood at Rs 1,601 crore from Rs 954.4 crore in Q3FY23. The EBITDA margin during the quarter expanded to 21.8% from 14.9% reported in the year-ago quarter.

The company’s US formulation business revenue was up by 28.9% YoY, and its Europe Formulation business revenue was up by 1.6% YoY.

In the last six months, the shares of the company have given a return of more than 16% against the benchmark Nifty50 index, which has given a return of around 11% in the same period.

At 11:24 am, the shares of Aurobindo Pharma were trading 0.80% higher at Rs 1,011.60 on NSE.